Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest announcement is out from Zai Lab Ltd ( (HK:9688) ).
Zai Lab reported fourth-quarter 2025 revenue of $127.6 million, up 17% year on year, and full-year 2025 revenue of $460.2 million, a 15% increase, while confirming its audited results were prepared under U.S. GAAP and that reconciled Hong Kong-compliant annual results will be published by March 31, 2026. Management highlighted 2025 as a year of disciplined execution, with the oncology candidate zocilurtatug pelitecan advancing toward becoming its first global oncology launch by 2026, a differentiated global pipeline progressing, and key regional programs such as KarXT in China and potential approvals for TIVDAK and TTFields positioning the company for multi-year growth and stronger financial performance.
The company emphasized the rapid pivotal development of zoci across multiple small cell lung cancer and extrapulmonary neuroendocrine carcinoma settings, leveraging its cross-border platform for speed and capital efficiency. It is also expanding the VYVGART franchise, preparing for KarXT’s commercial rollout following its inclusion in a national expert consensus for schizophrenia, and targeting pivotal data readouts in 2026 for povetacicept in IgA nephropathy and elegrobart in thyroid eye disease, moves that could further entrench Zai Lab as an emerging global biopharma leader and enhance its competitive position in specialty therapeutics.
The most recent analyst rating on (HK:9688) stock is a Hold with a HK$18.00 price target. To see the full list of analyst forecasts on Zai Lab Ltd stock, see the HK:9688 Stock Forecast page.
More about Zai Lab Ltd
Zai Lab Limited is a biopharmaceutical company operating between China and the U.S., focused on developing and commercializing innovative medicines in oncology, immunology, neuroscience and other serious diseases. The company builds a mix of global proprietary programs and regional partnerships, targeting both China’s large patient base and worldwide markets through an integrated U.S./China R&D and commercial infrastructure.
Average Trading Volume: 10,148,595
Technical Sentiment Signal: Sell
Current Market Cap: HK$16.89B
For detailed information about 9688 stock, go to TipRanks’ Stock Analysis page.